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Background
Current treatment of depression fails to achieve remission in 50% of patients. 
Combinations of two antidepressants are used by some Australian psychiatrists. 
Objective 
This article investigates the pros and cons of combination antidepressant therapy and 
provides suggestions for when to consider their use, which combinations to choose, and 
how to introduce combination antidepressant therapies.
Discussion
Combining two antidepressants is a controversial strategy, with supporters and critics 
arguing its efficacy and safety from opposing perspectives. The use of combination 
antidepressant therapies may facilitate remission from depression. However, there is 
limited evidence supporting these treatments, and safety concerns are often cited. There 
is some support for combination therapies in selected cases from international bodies. 
After considering risks and benefits on a case-by-case basis, careful use of selected 
combination antidepressant therapy may be one of a range of effective treatments for 
some individuals suffering from depression. 
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For 50% of sufferers, depression is a 
lifelong illness. A 23 year follow up of first 
episode depression showed the illness to 
be unremitting in 15% of patients, and 
recurrent in 35%.1 Analogous to cancer, 
failure to achieve total eradication of 
depressive illness (remission) by vigorous 
treatment worsens the prognosis 
regarding recovery and relapse. 
Despite government initiatives in recent years, 
many doctors still report to the authors a lack 
of easy access to psychiatrists for advanced 
pharmacological management of depression, 
increasing the burden on general practitioners. 
This article aims to examine the evidence 
regarding combination antidepressants, and 
discusses practical aspects of their use in the 
minority of patients who may benefit from this 
approach.
Australian and international 
views 
A number of guidelines have been published 
since 2008, summarising psychiatric practice 
in various countries. In the United Kingdom, 
the 2009 National Institute for Health and 
Clinical Excellence (NICE) National Clinical 
Practice Guideline 90 stated that ‘combining 
antidepressant drugs with different modes of 
action is increasingly used in clinical practice’;2 
and the 2009 Maudsley Prescribing Guidelines 
describe a selective serotonin reuptake inhibitor 
(SSRI) or venlafaxine combined with mirtazepine 
or mianserin for refractory depression as 
options among the ‘commonly used treatments 
generally well supported by published literature’.3 
In Canada, the 2009 Canadian Network for 
Mood and Anxiety Treatments (CANMAT) 
guidelines state (with respect to combination 
antidepressants) ‘the best available evidence is 
for add on treatment with mirtazapine/mianserin, 
or bupropion’, and state there is level 2 evidence 
for these combinations.4 The 2010 depression 
treatment guidelines of the American Psychiatric 
Association state that, for refractory depression, 
‘the addition of a second non-MAOI [monoamine 
oxidase inhibitors] antidepressant may be helpful, 
particularly for patients who have had a partial 
response to antidepressant monotherapy’.5
The Australian Therapeutic Guidelines: 
Psychotropic (2008) take a different position, 
stating ‘there is little evidence supporting the 
use of combined antidepressants in treatment 
resistant depression, and there are significant 
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A 2004 survey sent to all Australian 
consultants and nonconsultants in psychiatry 
(with a 33% response rate) showed that 76% 
of respondents (including 79% of consultant 
psychiatrists) had already used combination 
antidepressants.7 Some Australian authors 
have argued that, due to a paucity of evidence, 
combination antidepressant therapies should only 
be used as a last resort in specialist settings.8
What is the evidence base?
The only published, well funded trial of 
combination antidepressants has been as a 
treatment arm involving 565 patients as part of 
the STAR*D study.9 In this study, in part funded by 
the United States of America National Institute 
of Health, no additional safety precautions were 
considered necessary for the combinations used 
in this trial, being citalopram with the addition 
of sustained release bupropion (not available on 
the Pharmaceutical Benefits Scheme [PBS] in 
Australia for the treatment of depression), and 
at another level in the trial being venlafaxine 
combined with mirtazepine.
Small and medium sized trials, and multiple 
case reports, suggest there are benefits from 
combination antidepressants.10 In a meta-analysis 
of 27 trials involving 667 patients failing to 
respond adequately to monotherapy, lam et al11 
reported a 62% response rate from combination 
antidepressants. This result must be tempered by 
the very small number of randomised controlled 
trials and the large number of small case series 
included in this meta-analysis. 
Carpenter et al12 reported a double 
blind placebo controlled trial of adjunctive 
mirtazapine or placebo after failure to respond 
to antidepressant monotherapy in depressed 
patients (N=26), showing that 64% of combination 
antidepressant treated patients responded, 
including 45.4% achieving remission, whereas 
only 20% of monotherapy treated patients 
responded and 13.3% achieved remission.
Comparing combining antidepressants with 
switching antidepressants, half of the 61 patients 
who failed to respond to two monotherapy trials 
were given a third monotherapy of citalopram or 
bupropion, while the other half took combined 
citalopram and bupropion. Remission was 
four times more common in the combination 
antidepressant group than in the switched 
antidepressant group, with no significant 
difference in side effect burden when compared to 
monotherapy.13
A double blind study of 61 patients showed 
significant benefit when paroxetine was combined 
with mirtazapine, compared with monotherapy 
with either medication alone. Nonresponders to 
either antidepressant did significantly better when 
the other antidepressant was added.14 In a recent 
study, 105 patients were randomly assigned 
over 6 weeks to fluoxetine alone (25% achieved 
remission), or to three different combinations of 
antidepressants, achieving 52% remission for 
mirtazapine plus fluoxetine, 58% remission for 
mirtazapine plus venlafaxine, and 46% remission 
for mirtazapine plus bupropion. Furthermore, 
double blind withdrawal of one component 
of the combination over 6 months produced a 
relapse in 40% of subjects.15 In the same journal, 
examination of the findings raised issues such as 
the low dose of fluoxetine used and the 6 week 
duration of the trial. The results were seen as 
mainly supporting the addition of mirtazapine to 
reuptake inhibitors.16
A search of clinical trial registries shows 
that many further trials are underway or recently 
completed, including a National Institute of 
Health funded trial of combinations of bupropion, 
escitalopram, mirtazapine, and venlafaxine 
(ClinicalTrials.gov Identifier: NCT00590863). 
When to combine 
antidepressants
Before considering treatment for depression it is 
necessary to first consider and exclude any factors 
which may prevent remission, including accurate 
diagnosis, comorbitities, psychosocial factors and 
treatment adherence.10 Psychological therapies 
should also be considered as a first line treatment 
or as an add-on to pharmacotherapy.
While the evidence base for antidepressant 
monotherapy as a first line treatment for 
depression is strong, the evidence base for second 
line treatments when remission is not achieved 
is not as strong. Before considering combination 
antidepressants, numerous alternative therapies 
can be chosen, including antidepressant dose 
escalation, or switching to another antidepressant 
monotherapy. It is generally agreed that the 
addition of lithium or of atypical antipsychotics 
are effective treatment strategies for depression 
that has partially responded to an antidepressant. 
However, many of these options also have limited 
evidence bases, limited efficacy or their own 
safety concerns. Where such strategies have 
failed, or are not feasible financially, combination 
antidepressants may represent an effective 
next step. Initiating a nonpharmacological 
(psychological) therapy may be useful and is 
supported by both sides of this controversy. 
In Australia, combination antidepressants are 
used more commonly as a later treatment option, 
especially for partial responders to monotherapy. 
Blier et al15 point out that half of all patients 
discontinue antidepressant treatment within 6 
weeks from initiating treatment, highlighting the 
importance of initiating treatment with effective 
medications, or moving rapidly to consolidate  
and hopefully add to initial, but limited, treatment 
gains. 
How to combine antidepressants
In the absence of robust large trials in this area, 
Table 1 represents the experience and specialist 
discussions of one author (DH), who has used 
combination antidepressants in selected patients 
over a 20 year period. The second antidepressant 
should ideally have a complementary biochemical 
mechanism of action and acceptable side effects, 
such as adding reboxetine or mirtazapine to an 
SSRI. 
Ongoing titration of antidepressants to the 
patient’s symptoms is very useful in achieving 
compliance and remission. Patients can be 
advised to contact their doctor if there is symptom 
recurrence, such as when faced with extra stress, 
after a virus, or premenstrually, or if symptoms 
of overmedication appear, such as the ‘yES’ 
syndrome (yawning, Expression/word finding 
difficulty, Silly mistakes).17 The effects of dose 
change are usually evident within 2–3 days (based 
on the author’s clinical experience with many 
patients). As the use of combined antidepressants 
remains controversial in Australia, and is outside 
manufacturers’ guidelines, it is appropriate to 
notate that you have discussed this issue with the 
patient, and ideally with a psychiatrist, if this can 
be arranged. 
Which medications to combine
The ideal aim is to supplement the initial 
antidepressant (usually an SSRI) with an 
398  Reprinted from AUSTRAlIAN FAMIly PHySICIAN VOl. 40, NO. 6, JUNE 2011
clinicalCombination antidepressants – use by GPs and psychiatrists
antidepressants, but monitoring of blood pressure, 
biochemistry, haematology and electrocardiogram 
should be considered. The adverse effect burden 
of antidepressant combination treatment may 
approximate the cumulative adverse effect burden 
of the individual antidepressants. However, in 
two trials of antidepressants combined with 
bupropion or placebo, the sexual side effects 
of monotherapy were reduced,23 suggesting 
that in some cases, antidepressant combination 
therapy may have a side effect burden less than 




In the survey of Australian psychiatrists 
quoted earlier, 75% of respondents stated they 
believed GPs should be educated in the use of 
combination antidepressants.7 Balancing efficacy 
and safety, and considering at what stage to 
commence combination therapies, as well as 
whether or not such therapy requires a specialist 
setting or can be initiated by a GP, need to be 
decided ideally by considering the evidence. 
However, the evidence is equivocal, and the 
same evidence has been used to justify very 
different conclusions. There are no clear results 
based on solid, evidence based medicine to 
guide doctors in dealing with treatment resistant 
depression. General practitioners will have to 
consider the evidence for themselves and decide 
which, if any, combination therapy to initiate, 
and when to do so. 
 Combination antidepressants are one 
of several next-step options after limited 
benefit from an initial antidepressant; other 
options (especially dose escalation, switching 
the antidepressant of choice for addition to 
SSRIs. In the USA, the antidepressant bupropion 
(indicated in Australia only for tobacco cessation) 
is frequently combined with SSRIs.
Weighing relative risks
Critics often highlight unsafe combinations, 
which often include MAOIs resulting in severe 
reactions. However, MAOI combinations are now 
not recommended for general use by proponents 
of combination therapies. The most commonly 
reported life threatening situations due to the 
serotonin syndrome involve the use of MAOIs in 
combination with serotonin reuptake inhibitors, 
such as SSRIs and the phenylpiperidine series 
opioids.19 An Australian review stated ‘most cases 
of serotonin syndrome are self limiting’.20 Rare 
severe or life threatening cases were associated 
mainly with the use of MAOIs as part of combined 
antidepressants. It is therefore strongly advised 
that MAOIs not be initiated within 14 days of 
stopping any other antidepressant (or within 5 
weeks of stopping fluoxetine). Similarly, 14 days 
needs to elapse after ceasing an irreversible 
MAOI, before initiating another antidepressant. 
As the rate of combination antidepressant 
use is unknown in Australia, the frequency risk 
of the serotonin syndrome cannot be measured. 
Serotonin syndrome usually occurs within 
24–48 hours of increased serotonin availability, 
manifesting initially with sweating, tachycardia, 
tremor and hyper-reflexia. Abdominal cramps, 
diarrhoea, tachycardia and blood pressure 
changes may also occur. Agitation, confusion and 
coma are more serious events, and some fatalities 
have occurred in the past. Cyproheptadine 8–16 
mg reverses the symptoms in less severe cases, 
together with withdrawal of the causative agent. 
Patients with severe symptoms should be referred 
immediately to an emergency department.6,20 
Failure to achieve full remission from depression 
is associated with more chronic and recurrent 
illness, increased medical and psychiatric 
comorbidities, poorer social and functional 
outcomes, and increased economic costs.21 
Depression which has not been effectively treated 
is highly correlated with Australia’s weekly rate 
of 40 suicides and an estimated 1300 episodes of 
deliberate self harm.22 
There is no established evidence of long 
term complications from the use of combination 
antidepressant utilising a different chemical 
mechanism of action. A survey of Australian 
psychiatrists showed that combinations of various 
antidepressants with mirtazapine or reboxetine 
(both involving noradrenergic mechanisms) were 
among the most commonly used (Table 2).7 This 
survey preceded the recent reservations about 
the effectiveness of reboxetine as monotherapy. 
In all combinations, one must be aware of 
the potential extra side effects involving the 
use of two antidepressants, such as weight 
gain from mirtazapine, sexual problems from 
SSRIs, and anticholinergic side effects from 
reboxetine. The newly released antidepressant 
agomelatine (which is reported not to have these 
side effects) states in its product information 
that it does not interact with paroxetine.18 
Agomelatine has no effect on serotonin, so the 
serotonin syndrome would not be expected; it 
acts on melatonin, noradrenaline and dopamine 
pathways. Agomelatine may therefore become 
Table 1. How to combine 
antidepressants with an SSRI or SNRI
•	 Increase the dose of the initial 
antidepressant at 1–2 week intervals 
while progressive improvement 
occurs, up to the maximum 
recommended dose or maximum 
tolerated dose
•	 Revert to previous dose when no 
improvement has occurred with the 
last dose increase. Consider adding 
lithium or an atypical antipsychotic, 
or second antidepressant
•	 Add a low dose of a second 
antidepressant, eg. add mirtazepine 
or reboxetine to an SSRI
•	 Avoid combinations with MAOIs or 
fluvoxamine
•	 If benefit appears within 2 weeks, 
further increases in this second 
antidepressant are indicated 
•	 Titrate doses of antidepressants in 
response to symptom relapse, or 
overmedication symptoms such 
as yawning and word finding 
difficulties. If using tricyclics (not the 
ideal combination), measure trough 
serum levels
•	 Normal concentration and memory 
are the endpoint hallmarks of good 
biochemical control
•	 Expert opinion
Table 2. Australian psychiatrists’ use 
of combination antidepressants7 
Combination of any two 
antidepressants
76%
SSRI + tricylic 41%
Venlafaxine + mirtazepine 40%
SSRI + mirtazepine 37%
Other antidepressants + 
mirtazepine
21%
Reboxetine + other 
antidepressants
34%
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antidepressants, lithium and antipsychotics) are 
summarised elsewhere.24 This article describes 
the rationale and mechanism for adding a second 
antidepressant to build upon the benefits of the 
first antidepressant. Referral may therefore be 
essential for doctors, especially when faced 
with treatment resistant depression and its 
foreseeable consequences. The ideal scenario 
is to have such therapy from a psychiatrist, or 
to have regular telephone or email access to a 
psychiatrist (such as psychsupport.com.au or 
1800 200 588). However, where such specialist 
advice is not available, or where the advice is 
not acceptable to patients (such as advocating 
voluntary psychiatric hospitalisation and 
electroconvulsive therapy), there are potential 
benefits from considering the use of combination 
antidepressants.
Conclusion
There are many steps to potentiate the 
benefits of antidepressants, including lithium, 
antipsychotics and antidepressant combinations. 
Some combinations are associated with greater 
efficacy and equivalent safety compared to 
antidepressant monotherapy. As the evidence 
base has grown, and clinical experience has 
increased, combination antidepressants have 
been used more commonly in specialist settings. 
This article suggests that when adequate 
trials of monotherapy have not resulted in 
remission, a possible approach is to add a second 
antidepressant with a different mechanism of 
action, ideally with specialist review or liaison. 
Combination antidepressant treatment is widely 
accepted in many countries, particularly in large 
populations such as Canada and the USA.
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